Silexion Therapeutics Corp (SLXN) — Titan Protect Analysis

SLXN

Silexion Therapeutics Corp

Healthcare · ·

$4.67

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$2M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-7.62

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-897.5%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$60.00

+1185% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 2 analysts covering this stock

About Silexion Therapeutics Corp

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatmen

https://silexion.com

Country: Israel Employees: 13 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.371

Positive but modest risk-adjusted returns

Kelly Fraction

0.0388

Modest edge detected — smaller position warranted

Calmar Ratio

-0.949

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-94.7%

Historical annualised return based on price data

Max Drawdown

-99.9%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

-0.29

Very low correlation to market moves

52W High

$223.60

98% below the year high

52W Low

$2.31

102% above the year low

Avg Volume

571,067

Average daily shares traded — higher means easier to buy and sell

Short Ratio

0.5

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-59.70

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

683.51

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

$-7,491,125

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-12,910,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$60.00

Target Median

$60.00

Target Low

$60.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go